Successful Deals with PwC: Acquisition of Rivopharm by Laprophan Group

PwC is pleased to announce that it advised Laprophan Group, one of Morocco’s leading pharmaceutical groups, on the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specialised in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions. PwC provided Financial, Tax, HR and Pensions Due Diligence services to Laprophan.

Headquartered in Lugano, Switzerland, Rivopharm is a pharmaceutical company specialised in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions, and operates its own EU-approved manufacturing facility. The company manages a proprietary portfolio of approximately 125 molecules and nearly 1,500 SKUs distributed across more than 30 countries worldwide and generates annual revenue of approximately US$100 million. Its main entities include Rivopharm SA in Switzerland, Rivopharm UK in the United Kingdom, Holsten Pharma in Germany and Sanoswiss in Lithuania.

Founded more than 75 years ago and headquartered in Casablanca, Morocco, Laprophan is one of Morocco’s leading pharmaceutical groups, with a diversified portfolio of more than 500 products spanning 14 therapeutic areas and revenues exceeding US$250 million. The Group benefits from a long-standing presence in Morocco and an international footprint through its offices in India, the United Arab Emirates and Côte d’Ivoire. The acquisition was carried out through Europhan, Laprophan’s Luxembourg-based European platform.

This transaction brings together two highly complementary businesses with differentiated geographic footprints, strong industrial capabilities and meaningful commercial, regulatory and operational synergies. It marks Laprophan’s first acquisition in Europe and a transformational milestone in the Group’s development, significantly strengthening its European footprint and accelerating its ambition to build a differentiated international pharmaceutical platform spanning Europe, Africa, the Middle East and selected global markets.

The acquisition was completed on June 15, 2026. The financial terms of the transaction were not disclosed.

The PwC team

Financial Due Diligence

Luca Borrelli (Partner)
Ryan Thompson (Senior Manager)

Tax Due Diligence

Daniel Schmidt (Partner)
Matteo Gamboni (Senior Manager)
Olga Stöckli (Senior Consultant)
Valentina Franciolli (Senior Consultant)
Stefano Rappi (Consultant)
John Holt (Director –PwC UK)
Graham Payne (Senior Manager - PwC UK)
Hannah Ellis (Senior Consultant – PwC UK)

HR & Pensions Due Diligence:

Luca Borrelli (Partner)
Ryan Thompson (Senior Manager)